Identifying data regarding approaching end of life of drug delivery devices
The system uses battery voltage monitoring, error detection, and memory capacity tracking to accurately predict the end of life of drug delivery devices, improving reliability and preventing failures.
Patent Information
- Application Number
- JP2024518323
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-09-24
- Filing Date
- 2022-09-22
- Publication Date
- 2024-11-21
AI Technical Summary
Existing drug delivery devices lack effective methods to accurately identify the approaching end of their service life, leading to potential failures and inaccuracies in dose delivery.
The system evaluates battery voltage, detects errors, monitors memory storage capacity, and tracks elapsed time to generate precise indicators of the device's end of life, using a combination of firmware and electronic components to provide notifications.
This approach enhances the accuracy of identifying the end of life of drug delivery devices, ensuring reliable operation and preventing failures by providing timely notifications.
Smart Images

Figure 2024543302000001_ABST
Abstract
Description
[Technical field]
[0001] The present disclosure relates to identifying data relating to approaching end of life of a drug delivery device. [Background technology]
[0002] US8556847B2 and US7749186B2 relate to devices for delivering substances and methods of making and using the same, more particularly to medical devices for dosing or delivering products, such as injection devices, syringes, injection pens, etc., with which a user can self-administer a dose of a fluid product, such as insulin, growth hormone, or osteoporosis medication, etc. The injection device includes at least one sensor for detecting an operating process of the injection device, an electronic circuit connected to the sensor for determining the start and elapsed time of a useful life based on one or more sensor signals, and an output device connected to the circuit for providing a signal indicative of the end of the useful life. A method for determining the useful life of the injection device is also included, where the start of the useful life is determined by one or more sensors for detecting the operating process of the device, a signal is generated indicating the end of the useful life, and at least one optical, acoustic, or tactile output device is associated with the injection device to provide the signal indicative of the end of the useful life. A timer can be coupled to the electronic circuit for detecting one of the useful life or the operating time of the injection device. The signal indicating to the user the end of useful life may be output continuously or for a predetermined period of time after at least one sensor detects an attempted operating process. Summary of the Invention [Means for solving the problem]
[0003] The present disclosure describes an electronic system and method for identifying data relating to the approaching end of life of a drug delivery device, the identified data can be evaluated to notify a user of the drug delivery device of the approaching end of life of the drug delivery device.
[0004] In an aspect, the present disclosure provides an electronic system configured to determine data regarding the approach of the end of life of a drug delivery device based on one or more of the following: evaluating the voltage of an internal battery of the drug delivery device or drug delivery accessory device; detecting an error of the drug delivery device or drug delivery accessory device regarding the end of life of the drug delivery device; evaluating the storage capacity of a memory for recording doses discharged by the drug delivery device. By determining data based on the above, the reliability of the determination of the approach of the end of life of the drug delivery device is increased. For example, the characteristics of the internal batteries used in an injection pen regarding their voltage over the life of the device may improve the accuracy of the determination of the end of life of the drug delivery device. Moreover, some errors that may occur when the supply voltage of a drug delivery device such as an injection pen, for example from a battery, is no longer as stable as at the beginning of the life of the drug delivery device, may be detected to obtain data regarding the approach of the end of life. Another characteristic of injection pens in particular is the storage capacity of the dose recording memory, which may be limited. Therefore, the storage capacity that may decrease during the life of the drug delivery device may also be evaluated to obtain data regarding the end of life of the drug delivery device.
[0005] In another aspect, the present disclosure provides a computer-implemented method for determining data relating to the approach of the end of life of a drug delivery device based on one or more of the following: evaluating the voltage of an internal battery of the drug delivery device or drug delivery accessory, detecting an error of the drug delivery device or drug delivery accessory relating to the end of life of the drug delivery device, evaluating the storage capacity of a memory for recording doses dispensed by the drug delivery device. The method may be implemented, for example, as part of the firmware of an electronic system including a processor, in particular a microcontroller, implemented in the drug delivery device. The processor may, for example, execute after use of the drug delivery device, for example after a drug dose is dispensed, frequently, upon user interaction, for example when a user enters a command into a user interface of the drug delivery device or drug delivery accessory, when data is transferred from the electronic system to an external device, in particular a mobile computer (such as a smartphone, tablet computer, handheld computer, laptop computer, etc.), and / or at a predetermined time period without user interaction, for example weekly or monthly.
[0006] In an embodiment, assessing the voltage of an internal battery of the drug delivery device or drug delivery accessory may include measuring the voltage of the internal battery and outputting the measured voltage. For example, the characteristics of a typical battery used in a drug delivery device, such as an injection pen, exhibit a typical discharge behavior over its life that can be evaluated to obtain data regarding approaching end of life of the drug delivery device.
[0007] In an embodiment, the evaluation of the voltage of the internal battery of the drug delivery device or drug delivery accessory may include measuring the voltage of the internal battery and flagging if the measured voltage is lower than a first threshold. A voltage may be selected as the first threshold, indicating that the battery has left the "plateau" region of its output voltage, indicating that the battery is approaching the end of its life, in particular that it may soon be depleted. The flagging is part of the dosage record and may be stored with each dosage record in the on-board non-volatile memory of the drug delivery device or drug delivery accessory. Thus, the flag history may be evaluated from the stored dosage records indicating the approaching end of life of the battery, and therefore of the drug delivery device that uses that battery. The flag history may be advantageous when the battery has recovered after use, or when the temperature has risen slightly such that subsequent dosage records are not "flagged". Based on the flag history, an accurate evaluation of the approaching end of life of the battery can be obtained.
[0008] In an embodiment, evaluating the voltage of the internal battery of the drug delivery device or drug delivery accessory device may include measuring the voltage of the internal battery and storing an error code in non-volatile memory if the measured voltage is lower than a second threshold. A voltage level may be selected as the second threshold, which is slightly higher than the minimum voltage required for a component of the electronic system to operate normally, for example the minimum voltage level required for a processor or microcontroller to operate. The error code is then permanently stored in the non-volatile memory so that it can be recalled at a later time.
[0009] In an embodiment, detecting an error in the drug delivery device or drug delivery accessory device may include measuring a supply voltage of the processor and performing a processor reset if the measured supply voltage is below a third threshold, the performed processor reset being stored in the non-volatile memory as a detected error.
[0010] In an embodiment, detecting an error in the drug delivery device or drug delivery accessory device may include measuring a supply voltage of the processor and ceasing operation of the processor so long as the measured supply voltage is below a fourth threshold, the ceasing of operation of the processor being stored in non-volatile memory as a detected error.
[0011] In an embodiment, detecting an error in the drug delivery device or drug delivery accessory device may include evaluating one or more readings of a sensor of the drug delivery device or drug delivery accessory device, and detecting the error when evaluation of the one or more readings indicates a low supply voltage.
[0012] In an embodiment, assessing the storage capacity of the memory for recording doses ejected by the drug delivery layer may include determining the number of dose records ejected by the drug delivery device and currently stored in a pre-allocated storage area of the memory, and determining the remaining tower storage capacity based on the determined number and a maximum number of dose records available for storage in the pre-allocated storage area of the memory.
[0013] In an embodiment, assessing the storage capacity of the memory for recording doses ejected by the drug delivery device may include determining the number of remaining doses ejected by the drug delivery device by subtracting the number of most recent dose records stored in the memory from the maximum number of dose records available to be stored in a pre-allocated storage area of the memory.
[0014] In embodiments, data relating to the approach of the identified end of life of the drug delivery device may be evaluated and an indication of the approach of the end of life of the drug delivery device may be generated based on the evaluation. In particular, generating the indication may include generating a control signal to output the approach of the identified end of life of the drug delivery device on a display and / or visible via a light source, audible via an acoustic transducer, and / or felt via a vibrator.
[0015] In yet another aspect, the present disclosure provides a drug delivery device or drug delivery accessory comprising the electronic system disclosed herein and further comprising one or more of the following: a display, an acoustic transducer, a vibrator, a light source, a communication interface for establishing a communication connection with an external device, wherein the electronic system is configured to transmit data relating to the approach of an identified end of life of the drug delivery device to the external device for evaluation and / or output. [Brief description of the drawings]
[0016] [Figure 1] 1 illustrates an injection device according to an embodiment. [Diagram 2] FIG. 2 shows a schematic block diagram of an embodiment of a device controller. [Diagram 3] 1 shows the typical discharge behavior of a button cell used as the battery in an injection pen. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0017] In the following, embodiments of the present disclosure are described with respect to injection devices, particularly pen-type injection devices. However, the present disclosure is not limited to such applications and may be equally utilized with other types of drug delivery devices, particularly those with shapes other than pens. All absolute values are given herein by way of example only and should not be construed as limiting.
[0018] An example of an injection pen with a combined injection button and grip and its mechanical configuration are described in detail in International Patent Application WO2014033195A1. Another example of an injection device with separate injection button and grip components is described in WO2004078239A1.
[0019] In the following description, the terms "distal", "distally" and "distal end" refer to the end of the injection pen at which the needle is located, while "proximal", "proximal" and "proximal end" refer to the opposite end of the injection device at which the injection button or dose knob is located.
[0020] FIG. 1 shows an exploded view of an injection pen 1. The injection pen 1 of FIG. 1 is a prefilled disposable injection pen, which includes a housing 10, in which an insulin container 14 is accommodated, to which a needle 15 can be attached. The needle is protected by an inner needle cap 16 and either an outer needle cap 17 or another cap 18. The insulin dose to be discharged from the injection pen 1 can be programmed or "dialed" by turning the dose knob 12, and the currently programmed dose is then displayed, for example in multiples, via the dose window 13. For example, if the injection pen 1 is configured to administer human insulin, the dose can be displayed in so-called international units (IU), with 1 IU being the biological equivalent of approximately 45.5 micrograms (1 / 22 mg) of highly pure crystalline insulin. In injection devices for delivering insulin analogues or other drugs, other units can be used. It should be noted that the selected dose can equally be displayed in a different way than that shown in the dose window 13 of FIG. 1.
[0021] The dose window 13 may be in the form of an opening in the housing 10 that allows a user to view a limited portion of a dial sleeve 70 that is configured to move as the dose knob 12 is turned to provide a visual indication of the currently programmed dose. The dose knob 12 rotates in a helical path relative to the housing 10 when turned during programming. In this example, the dose knob 12 includes one or more formations 71 a, 71 b, 71 c to facilitate attachment of a data collection device (a drug delivery or injection accessory).
[0022] The injection pen 1 may be configured such that turning the dose knob 12 produces a mechanical click sound to provide audio feedback to the user. The dial sleeve 70 mechanically interacts with a piston in the insulin container 14. In this embodiment, the dose knob 12 also functions as an injection button. When the needle 15 is driven into the patient's skin area and the dose knob 12 is pressed axially, the insulin dose displayed in the viewing window 13 is expelled from the injection pen 1. If the needle 15 of the injection pen 1 remains in the skin area for a certain period of time after the dose knob 12 is pressed, a high percentage of the dose is actually injected into the patient's body. The expulsion of the insulin dose may also produce a mechanical click sound, which is different from the sound produced when the dose knob 12 is rotated while dialing the dose.
[0023] In this embodiment, during delivery of an insulin dose, the dose knob 12 moves axially and does not rotate back to its original position, while the dial sleeve 70 rotates back to its original position, e.g., to indicate a dose of zero units.
[0024] The injection pen 1 can be used for multiple injection processes until the insulin container 14 is empty or the expiration date of the medication within the injection pen 1 is reached (eg, 28 days after first use).
[0025] Furthermore, in order to expel air from the insulin container 14 and needle 15 before using the injection pen 1 for the first time, it may be necessary to perform a so-called "prime shot", for example by holding the injection pen 1 with the needle 15 facing upwards, selecting two units of insulin and pressing the dose knob 12. For ease of explanation, in the following it is assumed that the discharged amount substantially corresponds to the injected dose, whereby for example the amount of drug discharged from the injection pen 1 is equal to the dose received by the user. However, differences between the discharged amount and the injected amount (e.g. losses) may need to be taken into account.
[0026] As mentioned above, the dose knob 12 also functions as an injection button, whereby the same components are used for dialing and ejection. A sensor mechanism 215 (FIG. 2) including one or more optical sensors may be mounted in the injection button or dose knob 12 and configured to sense the relative rotational position of the dial sleeve 70 with respect to the injection button 12. This relative rotation equates to the size of the ejected or delivered dose and can be used to generate and store or display administration history information. The sensor mechanism 215 may include a first (optical) sensor 215a and a second (optical) sensor 215b. The sensor mechanism 215 may also be mounted on a drug delivery or injection accessory, which may be adapted for use with different injection devices 1 and configured to collect the data obtained by the sensor mechanism 215.
[0027] The device 1 or an accessory device for mounting to the device 1 may also include an electronic system 700, as shown diagrammatically in Fig. 2. The electronic system 700 may include a sensor mechanism 215 including two sensors 215a, 215b, and components for controlling the sensor mechanism 215 and performing other tasks such as communicating with external devices, processing user input, outputting information for a user, etc. Controlling the sensor mechanism 215 may in particular include driving at least one of the optical sensors 215a, 215b, where driving in particular means how to control the optical sensor to generate light pulses for measurement of the rotation of the encoder ring and to detect reflections of these measurement light pulses from a reflective area of the encoder. The electronic system may include one or more processors, such as, for example, a microprocessor, a digital signal processor (DSP), an application specific integrated circuit (ASIC), a field programmable gate array (FPGA), or the like; memory units 24, 25 including a main memory 24 and a program memory 25 capable of storing software executed by the processor mechanism 23; a communication unit or output 27, which may be a wireless communication interface for communicating with other devices via a wireless network such as Wi-Fi™ or Bluetooth®, and / or an interface for a wireless communication link, such as a socket for receiving, for example, a Universal Serial Bus (USB), mini-USB, or micro-USB connector; a display unit 30, such as, for example, an LCD (liquid crystal display), one or more LEDs, and / or an e-paper display; a user interface (UI) 31, such as, for example, one or more buttons and / or touch input devices; a power switch 28; and a battery 29.
[0028] The components 23, 24, 25, 27, 28, 29, 30, 31 may be soldered to a PCB that includes component wiring. The sensor mechanism 215 may be mounted on the PCB or wired to the processor mechanism 23. The implementation of the sensor unit 700 depends on the drug delivery device or drug delivery accessory in which it is to be incorporated. For example, a PCB with the components 23, 24, 25, 27, 28, 29, 30, 31 may be incorporated at the distal end of the infusion device 1 and the sensors 215a, 215b may be wired to the PCB. At least some of the components 23, 24, 25, 27 may also be included in a SoC (System on Chip) or a microcontroller.
[0029] The firmware stored in the program memory 25 may configure the processor mechanism 23 to control the sensor mechanism 215 to detect the discharge of a drug dose delivered using the device 1, with each of the sensors 215a, 215b outputting a sensor signal corresponding to the detected delivered drug dose. The processor mechanism 23 receives the sensor signal of each of the sensors 215a, 215b to obtain a reading of each sensor signal, which is processed to calculate the delivered dose. The reading may include, for example, one or more voltage samples of the analog voltage signal of the sensor 215a, 215b. The reading may also include an integral of the analog voltage signal of the sensor 215a, 215b over a certain time range. Instead of a voltage signal, a current, charge, or other output signal generated by the sensor may also be used to obtain a reading, for example, a frequency, a frequency shift of the sensor signal. A reading may be obtained by each sensor 215a, 215b during operation of the infusion device 1 to measure the number of units dispensed by the device 1.
[0030] The firmware may further configure the processor arrangement 23 to perform the functions described below for determining data relating to the approach of the end of life of the injection pen or device 1. In general, four main methods can be provided for determining data relating to the end of life, some of which also make it possible to track the approach of the end of life: 1. Battery voltage 2. Detecting device errors (end of life) 3. Elapsed Time 4.Memory storage capacity
[0031] These will be explained in more detail below using as an example the injection pen or device 1 shown in Figure 1. However, it should be noted that the functions described below are suitable for determining end-of-life data for any drug delivery device having at least one of the following functions: detecting device errors, storing a dosage record in a non-volatile memory, measuring the voltage of the device battery, connectivity functions, etc.
[0032] First, determining end of life data based on the voltage of the battery 29 of the electronic system 700 will be described.
[0033] Battery 29 may be a primary lithium cell, for example having a chemistry of Li / MnO2. The cell follows a typical discharge behavior 100 shown in Figure 3 (this discharge behavior is similar to that of a CR1225 button cell), with a steep initial drop 102 in voltage, followed by a long plateau 104 for most of the life, followed by a relatively steep decline at the end of life.
[0034] Thus, while battery voltage alone does not facilitate easily gauging the percentage of useful life, it can be used to identify data regarding approaching end of life, and in particular to use such identified data to provide early warning of approaching end of life.
[0035] Three main voltage-based functions can be implemented by firmware to determine the data. It should be noted that each of the functions can be implemented as a single functionality, or two or all three functions can be implemented together. The functions are based on measuring the voltage of the battery 29, which can be performed by an analog-to-digital converter (ADC) (not shown in FIG. 2) of the electronic system 700. The ADC can be integrated into the processor mechanism 23 or included in the sensor mechanism 215, for example, to convert analog signals from the sensors 215a, 215b to digital signals. Also, a separate ADC can be provided to measure the voltage of the battery 29 and digitize it for further processing by the processor mechanism 29.
[0036] The first voltage-based function is that the voltage of the battery 29 is measured at the end of every dose recording event and can be transmitted to an external device via the communication link between the external device and the communication unit 27, in particular as part of the extended dose recording, for every dose event and / or for every dose recording and manual synchronization event of the dose recording. This function can be performed in such a way that the measured value of the battery voltage is not stored in an internal non-volatile, e.g. flash memory, of the injection pen 1. Every time there is a communication event via the communication link between the communication unit 27 of the electronic system 700 of the pen 1 and the external device, the measured value of the current battery voltage can be communicated. Thus, the external device has data to make a decision by itself and to further communicate the end-of-life status of the pen. Also, independent of any communication event, the processor mechanism 23 can be configured by this first function to periodically perform a measurement of the current battery voltage, or a user input via the UI 31 and / or the toggling of the power switch can trigger such a measurement. The measured value of the battery voltage can also be output, for example for displaying it on the display unit 30.
[0037] The second voltage-based function is based on a first threshold th1 of the battery voltage as shown in FIG. 3. The first threshold may relate to a "low voltage flag" of the injection pen 1. This second function may in particular be for providing a first early warning of approaching end of life. For example, a (nominal) 3V lithium battery of the injection pen 1 spends most of its life at about 2.5V to 2.7V at a voltage plateau 104 after an initial drop 102 (under usage load). Thus, for a 3V lithium battery used as the battery 29, a "low voltage flag" can be set if the battery voltage measured at the end of dose delivery is less than, about, or higher than 2.4V (threshold th1 in FIG. 3). The "low voltage flag" can be stored in the internal non-volatile memory of the pen so that it is available and viewable in the history as part of the dose record, and not "flagged" in later records, in case the voltage could recover slightly or the temperature rise slightly. A threshold th1 may be selected to indicate that pen 1 is leaving the plateau region 104 and beginning to approach the end of its life (at the beginning of the steep decline 106).
[0038] A third voltage-based function is based on a second threshold th2 of the battery voltage as shown in FIG. 3. The second threshold may relate to an "extremely low voltage" error code of the injection pen 1. This third function may create an additional dose record with a special error code, which may be a permanently stored and readable historical event, indicating that the battery voltage measured at the end of the dose was lower than a certain threshold th2. The threshold th2 for "extremely low voltage" may be selected to occur before other errors in the pen 1 that start to occur when the supply voltage drops below a threshold at which the microprocessor can operate (see below). For example, for a 3V lithium battery, this threshold th2 may be set to about 2.3V and may be selected to allow for additional momentary voltage drops that may occur after a dose event when the pen 1 is performing a flash or communication of the user LEDs, which is a higher current event and therefore pulls the battery voltage lower.
[0039] The above mentioned functionality performs an evaluation of the voltage of the battery 29 of the injection pen 1, which makes it possible to determine data relating to the approaching end of life of the injection pen 1.
[0040] Secondly, determining end of life data based on detecting errors in the injector pen 1 is described.
[0041] Three error-based functions may be implemented by firmware for identifying data regarding the approaching end of life of the injector pen 1 using device errors.
[0042] The first error-based function may be based on the so-called "brown-out detection". The processor mechanism 23 may have a built-in function to perform a soft reset of the microprocessor when it detects that the supply voltage has fallen below a third threshold thmin (FIG. 3). This may continue the detection through software operation (time sample based). The third threshold thmin may be selected to activate a so-called brown-out reset at, for example, about 1.8V in the case of a 3V lithium battery as the battery 29. When the reset is triggered by the detection of a voltage of about 1.8V or less, the microprocessor of the processor mechanism 23 may register that a brown-out event has occurred. This detection may be used to generate a device error with a unique code of the brown-out by the processor mechanism 23. This may further create a permanently stored readable history event to indicate that a brown-out event has occurred. In the case of a brown-out event, this may represent a momentary reset of the software and therefore that any associated dosing event may have been overlooked or inaccurate. The firmware may therefore be implemented such that the aforementioned ultra-low voltage device error is intended to occur before the brown-out error.
[0043] A second error-based feature may be based on "power-on reset detection." This is similar to the brown-out detection mechanism, except that it occurs when the battery 29 supply voltage gets too low and the microprocessor stops running completely until the voltage rises again. This has the effect of "power cycling" and the microprocessor detects that it is restarting. Firmware may be implemented to assign a specific error code to this event and create a device error record.
[0044] A third error-based feature may be based on a "sensor health check". This exploits that the analog sensor readings from the sensors 215a, 215b are proportional to the supply voltage of the battery 29. Thus, as the battery voltage decreases, so does the sensor reading. This has the effect that in the case of the optical sensors 215a, 215b, the readings of the reflection of these measurement light pulses from the reflective area of the encoder decrease with decreasing voltage, and without a sensor health check these may decrease significantly and fall below the threshold between black and white. However, the sensor health check may detect that the last reading of the sensor 215a, 215b at the end of the dose was 125% of this threshold. Thus, a device error made in response to a sensor health check can be used as an end of life indicator before a dose recording error occurs.
[0045] The above-mentioned functionality performs error detection for the injection pen 1, thereby enabling data relating to the approaching end of life of the injection pen 1 to be identified.
[0046] The elapsed time, i.e. time of use, can be used as an end-of-life indicator. To generate a timestamp for all dose and error records, the injection pen 1 has a permanently running built-in clock, the "real-time clock" or RTC. To minimize the data storage space required for the timestamps, each timestamp can be stored as a time offset from the "first use time". When the device 1 is activated for the first time after manufacture, it can detect the time and date in UTC and store it as the first use time. It is therefore possible to determine how long the pen 1 has been operating for at any time after this first use. The first use time and the current time can be communicated automatically and on demand to an external device, for example via Bluetooth. The external device can thus obtain all the information and then determine end-of-life predictions etc. and communicate these further to the user.
[0047] In addition to the above schemes, there is also a time-related end-of-life indication. As previously mentioned, the timestamp for each dose can store an offset in minutes from the time of first use. A certain number of data bits can then be assigned to this offset to minimize and optimize the amount of data stored. The number of assigned data bits can correspond to 3.99 years of use. When this time offset is reached, a time error code can be created, stored, and transmitted in place of the timestamp. Receipt of this time error code by an external device indicates that the end-of-life state has been reached.
[0048] Third, determining end-of-life data based on a tabulation of memory storage capacity for recording doses expelled by a drug delivery device is described.
[0049] The non-volatile memory provided for storing the dosage records of the injection device 1 may have a limited capacity (for example it may be implemented as a flash memory with a limited storage capacity). To manage this limited storage capacity, an area of the memory may be allocated to the dosage records in advance. In such a case it is known from the beginning exactly how many dosage records can be created before the device reaches the end of its life (assuming each dosage record requires the same storage capacity).
[0050] Within the injection pen, capacity for, for example, 4500 dose records may be pre-allocated within the non-volatile dose record storage. At any point in time, the pen therefore knows how many dose records there were initially and how many are currently stored. It may make this information available to an external communications device so that accurate knowledge of the device's life status can be obtained, or it may be processed by the processor arrangement 23 to identify data relating to approaching end of life.
[0051] For example, the injection pen 1 may communicate the number of the latest dose records through the communication unit 27 as part of the extended dose record, so that every automatic or manual data connection event may provide this information. In addition, the dose storage capacity at the start may be available as part of a digital Unique Device Identification (UDI). The UDI may be made available by the external communication device on demand during every communication connection, in particular a Bluetooth connection. Thus, the external device can determine the number of remaining doses (= dose record capacity - latest number of dose records - 1), where the numbering of dose records may start from 0 for some injection devices. The external device may also calculate the percentage remaining or the percentage used.
[0052] Thus, the most recent dose record of 4499 indicates that the device has reached the end of its life (no further record storage is possible and the pen will cease functioning).
[0053] This calculation can essentially also be performed by the electronic system 700, i.e. the processor arrangement 23 configured as such by firmware. The result can then be shown on the display unit 30 and / or transmitted to an external device via the communication unit 27, or can be stored in the main memory 24 or in a non-volatile internal memory for later use.
[0054] Alternatives to this embodiment are possible, but not currently embodied: it would be possible to report the remaining number of recorded doses instead of the current number of recorded doses, i.e., counting down from the capacity towards zero, rather than counting up.
[0055] The identified data relating to the approaching end of life of the injection pen 1 can be further evaluated and an indication of the approaching end of life of the injection pen can be generated based on this evaluation. For example, the end of life of the injection pen 1 can be after the next x drug expulsions, which can be used to generate a corresponding indication, in particular for further processing by the processor mechanism 23 and / or for transmission to an external device via the unit 27. The indication can include generating a control signal for outputting the approaching end of life of the identified drug delivery device, for example visible on a display and / or via a light source, audible via an acoustic transducer and / or felt via a vibrator.
[0056] It should be noted that although the above description relates to firmware to be executed by the processor arrangement 23, the functionality disclosed herein may also be implemented at least in part as hardware, e.g., a (F)PGA ((field) programmable gate array), ASIC (application-specific integrated circuit).
[0057] It should also be noted that at least some of the functionality disclosed herein may also be performed by an external computing device communicatively coupled to the drug delivery device, such as the injection pen 1. For example, battery voltage measurements as well as detected errors may be transmitted to the external computing device for evaluation of the received end-of-life data.
[0058] The terms "drug" or "medicament" are used interchangeably herein to refer to a pharmaceutical formulation containing one or more active pharmaceutical ingredients or pharma- ceutically acceptable salts or solvates thereof, and optionally a pharma- ceutically acceptable carrier. An active pharmaceutical ingredient (API) is, in its broadest sense, a chemical structure that has a biological effect on humans or animals. In pharmacology, drugs or agents are used in the treatment, cure, prevention, or diagnosis of disease, or otherwise to improve physical or mental health. Drugs or agents may be used for a limited period of time, or periodically for chronic conditions.
[0059] As described below, a drug or agent may include at least one API, or a combination thereof, in various types of formulations for the treatment of one or more diseases. Examples of APIs may include small molecules with a molecular weight of 500 Da or less, polypeptides, peptides, proteins (e.g., hormones, growth factors, antibodies, antibody fragments, and enzymes), carbohydrates and polysaccharides, and acids, double-stranded or single-stranded DNA (including naked and cDNA), RNA, antisense nucleic acids such as antisense DNA and RNA, small interfering RNA (siRNA), ribozymes, genes, and oligonucleotides. Nucleic acids may be incorporated into molecular delivery systems such as vectors, plasmids, or liposomes. Mixtures of one or more drugs are also envisioned.
[0060] The drug or agent may be contained in a primary package or "drug container" adapted for use with the drug delivery device. The drug container may be, for example, a cartridge, syringe, reservoir, or other solid or flexible container configured to provide a suitable chamber for suitable storage (e.g., short-term or long-term storage) of one or more drugs. For example, in some instances, the chamber may be designed to store the drug for at least one day (e.g., from 1 to at least 30 days). In some instances, the chamber may be designed to store the drug for about one month to about two years. Storage may be at room temperature (e.g., about 20°C) or at low temperature (e.g., from about -4°C to about 4°C). In some instances, the drug container may be or include a dual-chamber cartridge configured to store two or more components of a drug formulation to be administered (e.g., an API and a diluent, or two drugs) separately, one in each chamber. In such instances, the two chambers of the dual-chamber cartridge may be configured to allow mixing of the two or more components prior to and / or during delivery into the human or animal body. For example, the two chambers may be configured such that they are in fluid communication with each other (e.g., by a conduit between the two chambers) to allow a user to mix the two components if desired prior to ejection. Alternatively, or in addition, the two chambers may be configured such that the components can be mixed while being ejected into the human or animal body.
[0061] The drugs or agents contained in the drug delivery devices described herein can be used for the treatment and / or prevention of various types of medical disorders. Examples of disorders include, for example, diabetes mellitus or complications of diabetes mellitus, such as diabetic retinopathy, thrombotic occlusions, such as deep vein or pulmonary thrombosis. Further examples of disorders are acute coronary syndromes (ACS), angina pectoris, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis, and / or rheumatoid arthritis. Examples of APIs and drugs are those listed in handbooks such as the Rote Liste 2014, for example, but not limited to, main groups 12 (antidiabetic drugs) or 86 (oncology drugs), and the Merck Index 15th Edition.
[0062] Examples of APIs for the treatment and / or prevention of type 1 or type 2 diabetes mellitus or complications of type 1 or type 2 diabetes mellitus include insulin, e.g., human insulin, or an insulin analog or derivative, glucagon-like peptide (GLP-1), a GLP-1 analog or GLP-1 receptor agonist, or an analog or derivative thereof, a dipeptidyl peptidase-4 (DPP4) inhibitor, or a pharma-ceutically acceptable salt or solvate thereof, or any mixture thereof. As used herein, the terms "analog" and "derivative" refer to a polypeptide having a molecular structure that can be derived formally from the structure of a naturally occurring peptide, e.g., that of human insulin, by deleting and / or substituting at least one amino acid residue present in the naturally occurring peptide and / or by adding at least one amino acid residue. The added and / or substituted amino acid residue can be either a codable amino acid residue or other naturally occurring residue, or a purely synthetic amino acid residue. Insulin analogs are also referred to as "insulin receptor ligands". In particular, the term "derivative" refers to a polypeptide having a molecular structure formally derivable from that of a naturally occurring peptide, such as that of human insulin, in which one or more organic substituents (e.g., fatty acids) are attached to one or more of the amino acids. Optionally, one or more amino acids present in the naturally occurring peptide may be deleted and / or substituted with other amino acids, including non-codeable amino acids, or amino acids, including non-codeable ones, have been added to the naturally occurring peptide.
[0063] Examples of insulin analogues are Gly(A21), Arg(B31), Arg(B32) human insulin (insulin glargine), Lys(B3), Glu(B29), human insulin (insulin lispro), Asp(B28) human insulin (insulin aspart), human insulin in which the proline in position B28 can be substituted with Asp, Lys, Leu, Val, or Ala and the Lys in position B29 can be substituted with Pro, Ala(B26) human insulin, Des(B28-B30) human insulin, Des(B27) human insulin, and Des(B30) human insulin.
[0064] Examples of insulin derivatives are e.g. B29-N-myristoyl-des(B30) human insulin, Lys(B29)(N-tetradecanoyl)-des(B30) human insulin (insulin detemir, Levemir®), B29-N-palmitoyl-des(B30) human insulin, B29-N-myristoyl human insulin, B29-N-palmitoyl human insulin, B28-N-myristoyl-LysB28ProB29 human insulin, B28-N-palmitoyl-LysB28ProB29 human insulin, B30-N-myristoyl-ThrB29LysB30 human insulin. , B30-N-palmitoyl-ThrB29LysB30 human insulin, B29-N-(N-palmitoyl-gamma-glutamyl)-des(B30) human insulin, B29-N-omega-carboxypentadecanoyl-gamma-L-glucamyl-des(B30) human insulin (insulin degludec, Tresiba®), B29-N-(N-lithocholyl-gamma-glutamyl)-des(B30) human insulin, B29-N-(ω-carboxyheptadecanoyl)-des(B30) human insulin, and B29-N-(ω-carboxyheptadecanoyl) human insulin.
[0065] Examples of GLP-1, GLP-1 analogs, and GLP-1 receptor agonists include, for example, lixisenatide (Lyxumia®), exenatide (Exendin-4, Byetta®, Bydureon®, a 39 amino acid peptide produced by the salivary glands of the Gila monster), liraglutide (Victoza®), semoglatide, taspoglatide, albiglatide (Syncria®), dulaglutide (Trulicity®), rExendin-4, CJC-1134-PC, PB-1023, TTP-054, languratide / HM-11260C (Efpeglenatide), HM-15211, C M-3, GLP-1 Erigen, ORMD-0901, NN-9423, NN-9709, NN-9924, NN-9926, NN-9927, Nodexene, Biador-GLP-1, CVX-096, ZYOG-1, ZYD-1, GSK-2374697, DA-3091, MAR-701, MAR709, ZP-2929, ZP-3 022, ZP-DI-70, TT-401 (Pegapamodtide), BHM-034, MOD-6030, CAM-2036, DA-15864, ARI-2651, ARI-2255, Tirzepatide (LY3298176), Bamadutide (SAR425899), Exenatide-XTEN, and Glucagon-Xten.
[0066] Examples of oligonucleotides are, for example, mipomersen sodium (Kynamro®), a cholesterol-lowering antisense therapeutic for the treatment of familial hypercholesterolemia, or RG012 for the treatment of Alport Syndrome.
[0067] Examples of DPP4 inhibitors are linagliptin, vildagliptin, sitagliptin, denagliptin, saxagliptin, and berberine.
[0068] Examples of hormones include pituitary or hypothalamic hormones or regulatory active peptides and their antagonists, such as gonadotropins (follitropin, lutropin, chorion gonadotropin, menotropin), somatropin (somatropin), desmopressin, terlipressin, gonadorelin, triptorelin, leuprorelin, buserelin, nafarelin, and goserelin.
[0069] Examples of polysaccharides include glycosaminoglycans, hyaluronic acid, heparin, low molecular weight heparin or very low molecular weight heparin, or derivatives thereof, or sulfated polysaccharides, such as the polysulfated forms of the above polysaccharides, and / or pharmaceutically acceptable salts thereof.An example of a pharmaceutically acceptable salt of polysulfated low molecular weight heparin is enoxaparin sodium.An example of a hyaluronic acid derivative is Hylan G-F20 (Synvisc®), sodium hyaluronate.
[0070] The term "antibody" as used herein refers to an immunoglobulin molecule or an antigen-binding portion thereof. Examples of antigen-binding portions of an immunoglobulin molecule include F(ab) and F(ab')2 fragments that retain the ability to bind antigen. Antibodies can be polyclonal, monoclonal, recombinant, chimeric, non-immunoglobulin or humanized, fully human, non-human (e.g., murine), or single chain antibodies. In some embodiments, antibodies have effector functions and can fix complement. In some embodiments, antibodies have reduced or no ability to bind Fc receptors. For example, antibodies can be isotypes or subtypes, antibody fragments, or variants that do not support binding to Fc receptors, e.g., have mutated or deleted Fc receptor binding regions. The term antibody also includes antibody binding molecules based on tetravalent bispecific tandem immunoglobulins (TBTI) and / or dual variable region antibody-like binding proteins (CODV) with cross-linking region orientation.
[0071] The term "fragment" or "antibody fragment" refers to a polypeptide derived from an antibody polypeptide molecule (e.g., antibody heavy and / or light chain polypeptides) that does not include the full-length antibody polypeptide, but still includes at least a portion of the full-length antibody polypeptide that is capable of binding to an antigen. An antibody fragment can include a truncated portion of a full-length antibody polypeptide, but the term is not limited to such truncated fragments. Antibody fragments that are useful in the present invention include, for example, Fab fragments, F(ab')2 fragments, scFv (single-chain Fv) fragments, linear antibodies, monospecific or multispecific antibody fragments such as bispecific, trispecific, tetraspecific and multispecific antibodies (e.g., diabodies, triabodies, tetrabodies), multivalent antibody fragments such as monovalent, bivalent, tetravalent and multivalent antibodies, minibodies, chelating recombinant antibodies, tribodies or bibodies, intrabodies, nanobodies, small modular immunopharmaceuticals (SMIPs), binding domain immunoglobulin fusion proteins, camelized antibodies, and VHH-containing antibodies. Other examples of antigen-binding antibody fragments are known in the art.
[0072] "Complementarity determining region" or "CDR" refers to short polypeptide sequences within the variable regions of both heavy and light chain polypeptides that are primarily responsible for mediating specific antigen recognition. The term "framework region" refers to amino acid sequences within the variable regions of both heavy and light chain polypeptides that are not CDR sequences but are primarily responsible for maintaining the correct positioning of the CDR sequences to allow antigen binding. Although framework regions themselves typically do not directly participate in antigen binding, as is known in the art, certain residues within the framework regions of a particular antibody may be directly involved in antigen binding or may affect the ability of one or more amino acids within the CDRs to interact with the antigen.
[0073] Examples of antibodies are anti-PCSK-9 mAb (e.g., alirocumab), anti-IL-6 mAb (e.g., sarilumab), and anti-IL-4 mAb (e.g., dupilumab).
[0074] Pharmaceutically acceptable salts of any API described herein are also contemplated for use in the drug or medicament in the drug delivery device. Pharmaceutically acceptable salts include, for example, acid addition salts and base salts.
[0075] Those skilled in the art will appreciate that modifications (additions and / or deletions) can be made to the various components of the APIs, formulations, devices, methods, systems, and embodiments described herein without departing from the full scope and spirit of the invention, and the invention encompasses such modifications and all equivalents thereof.
[0076] Exemplary drug delivery devices may include needle-based injection systems as described in Table 1 of ISO11608-1:2014(E) section 5.2. As described in ISO11608-1:2014(E), needle-based injection systems may be broadly categorized as multi-dose container systems and single-dose (partial or full discharge) container systems. The containers may be replaceable or integrated non-replaceable containers.
[0077] As further described in ISO11608-1:2014(E), a multi-dose container system may include a needle-based injection device with replaceable containers. In such systems, each container holds multiple doses and may be fixed or variable (pre-set by a user) in size. Other multi-dose container systems may include a needle-based injection device with an integrated non-replaceable container. In such systems, each container holds multiple doses and may be fixed or variable (pre-set by a user) in size.
[0078] As further described in ISO11608-1:2014(E), the single dose container system may include a needle-based injection device with replaceable containers. In one example of such a system, each container holds one dose and the entire deliverable amount is expelled (full expelled). In another example, each container holds one dose and a portion of the deliverable amount is expelled (partial expelled). As also described in ISO11608-1:2014(E), the single dose container system may include a needle-based injection device with an integrated non-replaceable container. In one example of such a system, each container holds one dose and the entire deliverable amount is expelled (full expelled). In another example, each container holds one dose and a portion of the deliverable amount is expelled (partial expelled).
Claims
1. The data regarding the approach of the end of life of the drug delivery device (1) are as follows: - assessing the voltage of the internal battery (29) of said drug delivery device (1) or drug delivery accessory; - detecting an error in the drug delivery device (1) or in the drug delivery accessory device relating to the end of life of the drug delivery device (1); - evaluation of the storage capacity of the memory (24) for recording the doses expelled by said drug delivery device (1); An electronic system (700) configured to determine based on one or more of:
2. 2. The electronic system (700) of claim 1, wherein the evaluation of the voltage of an internal battery (29) of the drug delivery device (1) or drug delivery accessory device comprises measuring the voltage of the internal battery (29) and outputting the measured voltage.
3. 3. The electronic system (700) of claim 1 or 2, wherein the evaluation of the voltage of the internal battery (29) of the drug delivery device (1) or drug delivery accessory device comprises measuring the voltage of the internal battery (29) and raising a flag if the measured voltage is lower than a first threshold (th1).
4. The electronic system (700) of claim 1, 2 or 3, wherein the evaluation of the voltage of the internal battery (29) of the drug delivery device (1) or drug delivery accessory device comprises measuring the voltage of the internal battery (29) and storing an error code in a non-volatile memory (24) if the measured voltage is lower than a second threshold (th2).
5. The electronic system (700) of any one of claims 1 to 4, wherein the detection of an error in the drug delivery device (1) or drug delivery accessory device comprises measuring a supply voltage of a processor (23) and performing a reset of the processor (23) if the measured supply voltage is lower than a third threshold value (thmin), the performed processor reset being stored in a non-volatile memory (24) as a detected error.
6. The electronic system (700) of any one of claims 1 to 5, wherein the detection of an error in the drug delivery device (1) or drug delivery accessory device comprises measuring a supply voltage of a processor (23) and stopping operation of the processor (23) as long as the measured supply voltage is lower than a fourth threshold, the stopping of operation of the processor being stored in a non-volatile memory (24) as a detected error.
7. The electronic system (700) of any one of claims 1 to 6, wherein the detection of an error in the drug delivery device (1) or drug delivery accessory device comprises evaluating one or more readings of sensors (215a, 215b) of the drug delivery device (1) or drug delivery accessory device and detecting an error when the evaluation of the one or more readings indicates a low supply voltage.
8. The electronic system (700) of any one of claims 1 to 7, wherein the assessment of the storage capacity of the memory (24) for recording doses discharged by the drug delivery device (1) includes determining the number of dose records discharged by the drug delivery device (1) and currently stored in a pre-allocated memory area of the memory (24), and determining the remaining storage capacity based on the determined number and a maximum number of dose records available for storage in the pre-allocated memory area in the memory (24).
9. The electronic system (700) of any one of claims 1 to 8, wherein the assessment of the storage capacity of the memory (24) for recording doses ejected by the drug delivery device (1) comprises determining the number of remaining doses ejected by the drug delivery device (1) by subtracting the number of latest dose records stored in the memory (24) from the maximum number of dose records available for storage in a pre-allocated memory area of the memory (24).
10. An electronic system (700) as claimed in any one of claims 1 to 9, further configured to evaluate the identified data relating to the approach of the end of life of the drug delivery device (1) and to generate an indication of the approach of the end of life of the drug delivery device (1) based on the evaluation, the indication in particular comprising a control signal for outputting the approach of the identified end of life of the drug delivery device (1) on a display (30) and / or visible via a light source, audible via an acoustic transducer and / or felt via a vibrator.
11. The data regarding the approach of the end of life of the drug delivery device (1) are as follows: - assessing the voltage of an internal battery (29) of said drug delivery device (1) or drug delivery accessory; - detecting errors in the drug delivery device (1) or in the drug delivery accessory device related to the end of life of the drug delivery device (1); - evaluating the storage capacity of a memory (24) for recording the doses expelled by said drug delivery device (1); A computer-implemented method for determining whether a particular
12. Evaluating the voltage of the internal battery (29) of the drug delivery device (1) or drug delivery accessory device comprises the following steps: - measuring the voltage of the internal battery (29) and outputting the measured voltage; measuring the voltage of the internal battery (29) and flagging if the measured voltage is below a first threshold; measuring the voltage of the internal battery (29) and storing an error code in the non-volatile memory (24) if the measured voltage is lower than a second threshold. The method of claim 11 , comprising one or more of:
13. Detecting an error in the drug delivery device (1) or drug delivery accessory device comprises the following steps: measuring a supply voltage of the processor (23) and executing a reset of the processor (23) if said measured supply voltage is lower than a third threshold (thmin), said executed processor reset being stored in a non-volatile memory (24) as a detected error; measuring the supply voltage of the processor (23) and, as long as said measured supply voltage is lower than a fourth threshold, stopping operation of said processor (23) and storing in a non-volatile memory (24) the stopping of said processor operation as a detected error; - evaluating one or more readings of a sensor (215a, 215b) of said drug delivery device (1) or drug delivery accessory device and detecting an error if the evaluation of said one or more readings indicates a low supply voltage.
13. The method of claim 11 or 12, comprising one or more of:
14. Evaluating the storage capacity of the memory (24) for recording the doses discharged by the drug delivery device (1) comprises the steps of: - determining the number of dosage records ejected by the drug delivery device (1) and currently stored in a pre-allocated storage area of the memory (24), and determining the remaining storage capacity based on the determined number and a maximum number of dosage records available for storage in the pre-allocated storage area of the memory (24); determining the number of remaining doses to be expelled by said drug delivery device (1) by subtracting the number of most recent dose records stored in said memory (24) from the maximum number of dose records available to be stored in a pre-allocated memory area of said memory (24).
14. The method of claim 11, 12, or 13, comprising one or more of:
15. The method according to any one of claims 11 to 14, further comprising evaluating the identified data relating to the approach of the end of life of the drug delivery device (1) and generating an indication of the approach of the end of life of the drug delivery device (1) based on the evaluation, wherein generating the indication particularly comprises generating a control signal for outputting the approach of the identified end of life of the drug delivery device (1) on a display (30) and / or visible via a light source, audible via an acoustic transducer and / or felt via a vibrator.
Citation Information
Patent Citations
Systems, devices, and methods relating to medication dose guidance
US20210050085A1
Methods and apparatus for aspects of a dose detection system
WO2021034902A2
